Nov, 2014
Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover Trials
EBIOMEDICINE
- Volume
- 1
- Number
- 1
- First page
- 80
- Last page
- 89
- Language
- English
- Publishing type
- Research paper (scientific journal)
- DOI
- 10.1016/j.ebiom.2014.11.001
- Publisher
- ELSEVIER SCIENCE BV
Background: The induction of heat shock protein (HSP) 72 by mild electrical stimulation with heat shock (MES + HS), which improves visceral adiposity and insulin resistance in mice, may be beneficial in treating metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM).
Methods: Using open-label crossover trials, 40 subjects with MS or T2DM were randomly assigned using computer-generated random numbers to 12 weeks of therapeutic MES + HS followed by 12 weeks of no treatment, or vice versa. During the intervention period, physical and biochemical markers were measured.
Findings: Compared to no treatment, MES + HS treatment was associated with a significant decrease in visceral adiposity (-7.54 cm(2) (-8.61%), 95% CI -8.55 to -6.53 (p=0.037) in MS, -19.73 cm(2) (-10.89%), 95% CI -20.97 to -18.49 (p=0.003) in T2DM). Fasting plasma glucose levels were decreased by 3.74 mg/dL (-5.28%: 95% CI -4.37 to -3.09 mg/dL, p = 0.029) in MS and by 14.97 mg/dL (10.40%: 95% CI -15.79 to 14.15 mg/dL, p < 0.001) in T2DM, and insulin levels were also reduced by 10.39% and 25.93%, respectively. HbA1c levels showed a trend toward reduction (-0.06%) in MS, and was significantly declined by -0.43% (95% CI - 0.55 to -0.31%, p = 0.009) in T2DM. HbA1c level of less than 7.0% was achieved in 52.5% of the MES + HS-treated T2DM patients in contrast to 15% of the non-treated period. Several insulin resistance indices, inflammatory cytokines or adipokines, including C-reactive protein, adiponectin, and tumor necrosis factor-a, were all improved in both groups. In isolated monocytes, HSP72 expression was increased and cytokine expression was reduced following MES + HS treatment. Glucose excursions on meal tolerance test were lower after using MES + HS in T2DM.
Interpretation: This combination therapy has beneficial impacts on body composition, metabolic abnormalities, and inflammation in subjects with MS or T2DM. Activation of the heat shock response by MES+ HS may provide a novel approach for the treatment of lifestyle-related diseases.
Funding: Funding for this research was provided by MEXT KAKENHI (Grants-in-Aid for Scientific Research from Ministry of Education, Culture, Sports, Science and Technology, Japan). (C) 2014 The Authors. Published by Elsevier B.V.
Methods: Using open-label crossover trials, 40 subjects with MS or T2DM were randomly assigned using computer-generated random numbers to 12 weeks of therapeutic MES + HS followed by 12 weeks of no treatment, or vice versa. During the intervention period, physical and biochemical markers were measured.
Findings: Compared to no treatment, MES + HS treatment was associated with a significant decrease in visceral adiposity (-7.54 cm(2) (-8.61%), 95% CI -8.55 to -6.53 (p=0.037) in MS, -19.73 cm(2) (-10.89%), 95% CI -20.97 to -18.49 (p=0.003) in T2DM). Fasting plasma glucose levels were decreased by 3.74 mg/dL (-5.28%: 95% CI -4.37 to -3.09 mg/dL, p = 0.029) in MS and by 14.97 mg/dL (10.40%: 95% CI -15.79 to 14.15 mg/dL, p < 0.001) in T2DM, and insulin levels were also reduced by 10.39% and 25.93%, respectively. HbA1c levels showed a trend toward reduction (-0.06%) in MS, and was significantly declined by -0.43% (95% CI - 0.55 to -0.31%, p = 0.009) in T2DM. HbA1c level of less than 7.0% was achieved in 52.5% of the MES + HS-treated T2DM patients in contrast to 15% of the non-treated period. Several insulin resistance indices, inflammatory cytokines or adipokines, including C-reactive protein, adiponectin, and tumor necrosis factor-a, were all improved in both groups. In isolated monocytes, HSP72 expression was increased and cytokine expression was reduced following MES + HS treatment. Glucose excursions on meal tolerance test were lower after using MES + HS in T2DM.
Interpretation: This combination therapy has beneficial impacts on body composition, metabolic abnormalities, and inflammation in subjects with MS or T2DM. Activation of the heat shock response by MES+ HS may provide a novel approach for the treatment of lifestyle-related diseases.
Funding: Funding for this research was provided by MEXT KAKENHI (Grants-in-Aid for Scientific Research from Ministry of Education, Culture, Sports, Science and Technology, Japan). (C) 2014 The Authors. Published by Elsevier B.V.
- Link information
- ID information
-
- DOI : 10.1016/j.ebiom.2014.11.001
- ISSN : 2352-3964
- Pubmed ID : 26137510
- Web of Science ID : WOS:000219068900016